Novel and validated titrimetric method for determination of selected angiotensin-II-receptor antagonists in pharmaceutical preparations and its comparison with UV spectrophotometric determination

Journal of Pharmaceutical Analysis

Volumn 2, Issue 6, 2012, Pages 470-477

  Patil, Shrikant H ^a   Janjale, Minakshi V ^b  

^a Department of Pharmacology   (India)

^b Department of Pharmaceutics SSJIPER ^*  (India)

Author keywords

Angiotensin II receptor antagonists; Titrimetric assay; UV spectrophotometry; Validation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; EPROSARTAN; IRBESARTAN; MESYLIC ACID; TELMISARTAN; VALSARTAN;

ACCURACY; AQUEOUS SOLUTION; ARTICLE; DRUG DETERMINATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PH; POTENTIOMETRIC TITRATION; QUALITY CONTROL; TITRIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 84925838398     PISSN: 20951779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpha.2012.03.009     Document Type: Article

References (46)

1. B. Pitt, and M.A. Konstam Overview of angiotensin II-receptor antagonists Am. J. Cardiol. 82 1998 47S 48S
2. R. Willenheimer, B. Dahlof, and E. Rydberg AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions Eur. Heart J. 20 1999 997 998
3. I.C. Johnston, M. Naitoh, and L.M. Burrell Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues J. Hypertens. Suppl. 15 1997 S3 S4
4. T. Unger Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different Am. J. Cardiol. 84 1999 9S 10S
5. B. Porta Oltra, C. Borrás Almenar, and N.V. Jiménez Torres Therapeutic interchange standardization for angiotensin II receptor antagonists in the treatment of hypertension in the hospital setting Farm. Hosp. 29 2005 104 112
6. B. Schmidt, and B. Schieffer Angiotensin II AT1 receptor antagonists: clinical implications of active metabolites J. Med. Chem. 46 2003 2261 2270
7. Ch. Hempen, L. Gläsle-Schwarz, and U. Kunz Determination of telmisartan in human blood plasma: Part I: immunoassay development Anal. Chim. Acta 560 2006 35 40
8. E. Cagigal, L. González, and R.M. Alonso Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine Talanta 54 2001 1121 1133
9. A.H. Prabhakar, and R. Giridhar A rapid colorimetric method for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage form J. Pharm. Biomed. Anal. 27 2002 861 866
10. O.C. Lastra, I.G. Lemus, and H.J. Sánchez Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets J. Pharm. Biomed. Anal. 33 2003 175 180
11. S. Tatar, and S. Saglik Comparison of UV- and second derivative- spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation J. Pharm. Biomed. Anal. 30 2002 371 375
12. M.G. Quaglia, E. Donati, and G. Carlucci Determination of losartan and hydrochlorothiazide in tablets by CE and CEC J. Pharm. Biomed. Anal. 29 2002 981 987
13. M. Zhang, F. Wei, and Y.F. Zhang Novel polymer monolith microextraction using a poly(methacrylic acid-ethylene glycol dimethacrylate) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrophoresis J. Chromatogr. A 1102 2006 294 301
14. S. Hillaert, T.R. De Beer, and J.O. De Beer Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists J. Chromatogr. A 984 2003 135 146
15. R.C. Williams, M.S. Alasandro, and V.L. Fasone Comparison of liquid chromatography, capillary electrophoresis and super-critical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets J. Pharm. Biomed. Anal. 14 1996 1539 1546
16. S. Hillaert, and W. Van den Bosshe Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis J. Pharm. Biomed. Anal. 31 2003 329 339
17. J. Nie, M. Zhang, and Y. Fan Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine J. Chromatogr. B 828 2005 62 69
18. D.E. Lundberg Jr., C.R. Person, and S. Knox Determination of SK and F 108566 (Teveten(R)) in human plasma by reversed-phase high-performance liquid chromatography J. Chromatogr. B 707 1998 328 329
19. S.Y. Chang, D.B. Whigan, and N.N. Vachharajani High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine J. Chromatogr. B 702 1997 149 150
20. E. Francotte, A. Davatz, and P. Richert Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester J. Chromatogr. B 686 1996 77 78
21. A. Soldner, H. Spahn-Langguth, and E. Mutschler HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats J. Pharm. Biomed. Anal. 16 1998 863 864
22. D. Farthing, D. Sica, and I. Fakhry Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate J. Chromatogr. B 704 1997 374 375
23. H. Lee, H.O. Sim, and H.S. Lee Simultaneous determination of losartan and active metabolite EXP3174 in rat plasma by HPLC with column switching Chromatographia 42 1996 39 40
24. C.I. Furtek, and M.W. Lo Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography J. Chromatogr. 111 1992 295 296
25. L. González, J.A. López, and R.M. Alonso Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection J. Chromatogr. A 949 2002 49 60
26. H. Stenhoff, P.O. Lagerstrom, and C. Andersen Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection J. Chromatogr. B 731 1999 411 412
27. M.A. Ritter, C.I. Furtek, and M.W. Lo An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection J. Pharm. Biomed. Anal. 15 1997 1021 1022
28. L. Kristoffersen, E. Leere Oiestad, and M. Stokke Opdal Simultaneous determination of 6 beta-blockers, 3 calcium-channel antagonists, 4 angiotensin-II antagonists and 1 antiarrhytmic drug in post-mortem whole blood by automated solid phase extraction and liquid chromatography mass spectrometry, Method development and robustness testing by experimental design J. Chromatogr. B 850 2007 147 160
29. T. Iwasa, T. Takano, and K. Hara Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry J. Chromatogr. B 734 1999 325 326
30. Z.X. Zhao, Q.X Wang, and E.W. Tsai Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS J. Pharm. Biomed. Anal. 20 1999 129 130
31. N. Ferreirós, G. Iriarte, and R.M. Alonso Development of a solid phase extraction procedure for HPLC-DAD determination of several angiotensin II receptor antagonists in human urine using mixture design Talanta 73 2007 748 756
32. N. Koseki, H. Kawashita, and H. Hara Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry J. Pharm. Biomed. Anal. 43 2007 1769 1774
33. N. Torrealday, L. González, and R.M. Alonso Experimental design approach for the optimisation of a HPLC-fluorimetric method for the quantitation of the angiotensin II receptor antagonist telmisartan in urine J. Pharm. Biomed. Anal. 32 2003 847 857
34. A.K. Shakya, Y.M. Al-Hiari, and O.M.O. Alhamami Liquid chromatographic determination of irbesartan in human plasma J. Chromatogr. B 848 2007 245 250
35. P. Li, Y. Wang, and Y. Wang Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry J. Chromatogr. B 828 2005 126 129
36. J. Macek, J. Klima, and P. Ptácek Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography J. Chromatogr. B 832 2006 169 172
37. N. Ferreirós, G. Iriarte, and R.M. Alonso Validation of a solid phase extraction-high performance liquid chromatographic method for the determination of eprosartan in human plasma J. Chromatogr. A 1119 2006 309 314
38. D. Liu, P. Hu, and N. Matsushima Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry J. Chromatogr. B 856 2007 190 197
39. N. Daneshtalab, R.Z. Lewanczuk, and F. Jamali High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method J. Chromatogr. B 766 2002 345 349
40. N. Erk Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography J. Chromatogr. B 784 2003 195 201
41. H. Li, Y Wang, and Y. Jiang A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma J. Chromatogr. B 852 2007 436 442
42. M. Polinko, K. Rifle, and H. Song Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry J. Pharm. Biomed. Anal. 33 2003 73 84
43. L. González, R.M. Alonso, and R.M. Jiménez A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine Chromatographia 52 2000 735 740
44. D.L. Hertzog, J. Finnegan McCafferty, and X. Fang Development and validation of a stability-indicating HPLC method for the simultaneous determination of Losartan potassium, hydrochlorothiazide, and their degradation products J. Pharm. Biomed. Anal. 30 2002 747 760
45. A.I. Vogel Quantitative Inorganic Analysis Including Elementary Instrumental Analysis 3rd ed. 1962 The English Language Book Society and Longman London pp. 242-243
46. E.P. Serjeant Potentiometry and Potentiometric Titrations 1984 Wiley New York pp. 98-99